Seven criteria, each scored 0 to 100 on a published scale, weighted into one number.
Strong. Indivior Pharmaceuticals, Inc. scores higher than 98% of the 1,794 companies Ryufin scores.
Carried by valuation and return on new capital, held back by earnings quality.
Healthcare median 29 · all companies 57
26% of the score, 37% here after data gaps
Indivior Pharmaceuticals, Inc. is valued at 12.2x its operating profit, including debt: an ordinary multiple.
Taken out: its 18% is shared by the others
Fewer than three years of operating profit and capital on file.
16% of the score, 23% here after data gaps
For every dollar of operating profit earned over 4 years, yearly profit grew by 237 cents.
14% of the score, 20% here after data gaps
How management spends the money: shares bought back or issued, and whether assets grow faster than the business they serve.
Taken out: its 12% is shared by the others
Fewer than five years of margins on file.
8% of the score, 11% here after data gaps
What the debt weighs against the profit that has to carry it.
6% of the score, 9% here after data gaps
Whether the reported profit arrives as cash, and whether the accounts show the usual signs of stretching.
Each criterion earns 0 to 100 points on the scale drawn under it, and the RyuScore is their average weighted 26, 18, 16, 14, 12, 8 and 6. Scales bend in the company's favour between their ends, so an ordinary figure is never already near zero. For INDV, return on capital and cycle position could not be measured from the filings, so they are taken out and the remaining weights scale up.
Built from the company's annual and quarterly filings with the SEC and today's share price. Banks, insurers and property trusts are not scored: their debt is their raw material, so these yardsticks mean something else there. Figures as of 2026-06-30, latest annual report FY2025.
Ranks #1 of 29 by RyuScore